Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Gene Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06417814
What this trial is testing

Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-small Cell Lung Cancer
AstraZeneca 744
Not applicableNo Longer AvailableNCT02547675
What this trial is testing

Rociletinib (CO-1686) USA Expanded Access Program

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc.
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Very early researchStudy completedNCT03755102
What this trial is testing

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Who this might be right for
EGFR Gene MutationLung CancerLung Cancer Metastatic
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)Study completedNCT06348888
What this trial is testing

Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation+1 more
Bayer 30
Not applicableStudy completedNCT05517083
What this trial is testing

Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Pusan National University Hospital 41
Not applicableUnknownNCT00903292
What this trial is testing

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Non-Small Cell Lung Cancer
National Cheng-Kung University Hospital 52
Testing effectiveness (Phase 2)UnknownNCT05267288
What this trial is testing

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Who this might be right for
PFS
Qingdao Central Hospital 30
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06436144
What this trial is testing

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIB+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 93
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Not applicableStudy completedNCT03137264
What this trial is testing

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT02444819
What this trial is testing

Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 33
Testing effectiveness (Phase 2)UnknownNCT01749072
What this trial is testing

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEffects of Chemotherapy
Peking Union Medical College Hospital 120
Testing effectiveness (Phase 2)Looking for participantsNCT07073365
What this trial is testing

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor
Pusan National University Hospital 70
Large-scale testing (Phase 3)UnknownNCT02886195
What this trial is testing

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

Who this might be right for
EGFR Gene Mutation
Fujian Cancer Hospital 120
Testing effectiveness (Phase 2)Study completedNCT06521034
What this trial is testing

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Sensitizing Mutation
Yongchang Zhang 124
Testing effectiveness (Phase 2)UnknownNCT01470716
What this trial is testing

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Who this might be right for
NSCLC Stage IINSCLC, Stage IIIA
National Cancer Center, Korea 26
Testing effectiveness (Phase 2)Looking for participantsNCT06192849
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD 20
Testing effectiveness (Phase 2)UnknownNCT03396185
What this trial is testing

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon Small Cell Lung Cancer Stage IIIB
Betta Pharmaceuticals Co., Ltd. 30
Next Page